<DOC>
	<DOCNO>NCT00847197</DOCNO>
	<brief_summary>This study evaluate lipid-modifying effect tolerability MK1903 compare placebo patient dyslipidemia statin lipid-modifying therapy .</brief_summary>
	<brief_title>A Study Evaluate MK1903 Patients With Dyslipidemia ( MK1903-004 )</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Participant statin lipidmodifying therapy Low moderate risk participant Male participant , female participant reproductive potential Female participant reproductive potential Participant pregnant , breastfeeding , expect conceive study Participant history cancer within 5 year study ( except certain type skin cervical cancer ) Participant user recreational illicit drug recent history drug and/or alcohol abuse Participant donate receive blood within 8 week study start intend give/receive blood study Participant consume 3 alcoholic drink per day 14 alcoholic drink per week Participant currently experience menopausal hot flash Participant currently engage vigorous exercise aggressive diet regimen Participant high risk heart condition Participant Type 1 Type 2 diabetes mellitus Participant poorly control cardiac arrhythmia Participant history stroke hemorrhage Participant poorly control high blood pressure Participant thyroid condition endocrine/metabolic disease would affect serum lipid Participant disease kidney liver Participant ulcer within 3 month screen Participant Human Immunodeficiency Virus ( HIV ) positive Participant take cyclical hormonal contraceptive noncontinuous hormone replacement therapy Participant take take Organic Anion Transporter ( OAT1/3 ) inhibitor/substrate within 3 day screen Participant take antiobesity medication within 3 month screen Participant take coumarins Participant take Nonsteroidal Antiinflammatory Drugs ( NSAIDs ) ( acetaminophen Cyclooxygenase2 ( COX2 ) inhibitor allow ) Participant take 100 mg aspirin per day Participant treat oral , intravenous , injected corticosteroid anabolic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>